A small study suggests it might be possible to shorten the length of expensive drug treatment for chronic hepatitis C virus (HCV), potentially cutting treatment time in half for 50% of patients. But managed care pharmacy clinicians say the results are far from ready to implement widely, and it’s possible the new approach might not even save money.
- People on the Move
- Medicare and Medicaid
- Datapoint, Medicare and Medicaid
- Abstract, Health Plans
- Datapoint, Drug Benefits, Medicare and Medicaid